- Moderate to Severe PC
- Adults, Age 18 or Older
- Able and willing to comply with all protocol-required activities
Hello, you are using an old browser that's unsafe and no longer supported. Please consider updating your browser to a newer version, or downloading a modern browser.
We are currently enrolling for the VAPAUS study, a pivotal phase 3 multicenter clinical study evaluating the safety and efficacy of QTORINTM rapamycin 3.9% in adults with moderate to severe pachyonychia congenita.